Sanofi (SNYNF) FDA Approvals $96.45 -0.36 (-0.37%) As of 03:14 PM Eastern Add Compare Share Share FDA Events Stock AnalysisChartFDA EventsFinancialsNews and TrendsSEC Filings Sanofi's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Sanofi (SNYNF). Over the past two years, Sanofi has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Libtayo. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Libtayo (cemiplimab) FDA Regulatory Events Libtayo (cemiplimab) is a drug developed by Sanofi for the following indication: Advanced Cervical Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Data - October 25,2026Data Drug: Libtayo (cemiplimab)Announced Date: October 25, 2026Indication: Advanced Cervical CancerOther Companies Involved: NASDAQ:REGN NASDAQ:SNY AnnouncementRegeneron Pharmaceuticals, Inc announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for patients with cutaneous squamous cell carcinoma (CSCC) at a high risk of recurrence after surgery and radiation.Read AnnouncementPositive Opinion - October 16,2026Positive Opinion Drug: Libtayo (cemiplimab)Announced Date: October 16, 2026Indication: Advanced Cervical CancerOther Companies Involved: NASDAQ:REGN NASDAQ:SNY AnnouncementRegeneron Pharmaceuticals, Inc announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo® (cemiplimab) across all approved indications.AI SummaryRegeneron Pharmaceuticals said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended an alternative dosing schedule for Libtayo (cemiplimab) across all its approved uses in the European Union. The recommendation would let patients switch, after 12 weeks of treatment with 350 mg every three weeks, to a 700 mg dose given every six weeks. The infusion would take 30 minutes. The CHMP also recommended allowing the 350 mg dose to be infused over 15 to 30 minutes, rather than 30 minutes, for patients whose first infusion was well tolerated. This could shorten treatment visits by up to half. The recommendation is based on drug-level modeling and safety and effectiveness data from Libtayo’s clinical program. The European Commission is expected to make the final decision in the coming months. The six-week schedule is already approved in the EU for certain patients receiving Libtayo after surgery and radiation to reduce the risk of high-risk cutaneous squamous cell skin cancer returning.Read Announcement Sanofi FDA Events - Frequently Asked Questions Has Sanofi received FDA approval? As of now, Sanofi (SNYNF) has not received any FDA approvals for its therapy in the last two years. What drugs has Sanofi submitted to the FDA? In the past two years, Sanofi (SNYNF) has reported FDA regulatory activity for Libtayo (cemiplimab). What is the most recent FDA event for Sanofi? The most recent FDA-related event for Sanofi occurred on October 25, 2026, involving Libtayo (cemiplimab). The update was categorized as "Data," with the company reporting: "Regeneron Pharmaceuticals, Inc announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for patients with cutaneous squamous cell carcinoma (CSCC) at a high risk of recurrence after surgery and radiation." What conditions do Sanofi's current drugs treat? Currently, Sanofi has one therapy (Libtayo (cemiplimab)) targeting the following condition: Advanced Cervical Cancer. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Aclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA EventsCorbus Pharmaceuticals FDA EventsCardiff Oncology FDA EventsCytokinetics FDA EventsEstrella Immunopharma FDA EventsCybin FDA EventsIDEAYA Biosciences FDA EventsIN8bio FDA EventsLantheus FDA EventsMediWound FDA EventsMetaVia FDA EventsRadiopharm Theranostics FDA EventsRein Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies AstraZeneca FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for OTCMKTS:SNYNF last updated on 10/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Data - October 25,2026Data Drug: Libtayo (cemiplimab)Announced Date: October 25, 2026Indication: Advanced Cervical CancerOther Companies Involved: NASDAQ:REGN NASDAQ:SNY AnnouncementRegeneron Pharmaceuticals, Inc announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for patients with cutaneous squamous cell carcinoma (CSCC) at a high risk of recurrence after surgery and radiation.Read Announcement
Positive Opinion - October 16,2026Positive Opinion Drug: Libtayo (cemiplimab)Announced Date: October 16, 2026Indication: Advanced Cervical CancerOther Companies Involved: NASDAQ:REGN NASDAQ:SNY AnnouncementRegeneron Pharmaceuticals, Inc announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo® (cemiplimab) across all approved indications.AI SummaryRegeneron Pharmaceuticals said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended an alternative dosing schedule for Libtayo (cemiplimab) across all its approved uses in the European Union. The recommendation would let patients switch, after 12 weeks of treatment with 350 mg every three weeks, to a 700 mg dose given every six weeks. The infusion would take 30 minutes. The CHMP also recommended allowing the 350 mg dose to be infused over 15 to 30 minutes, rather than 30 minutes, for patients whose first infusion was well tolerated. This could shorten treatment visits by up to half. The recommendation is based on drug-level modeling and safety and effectiveness data from Libtayo’s clinical program. The European Commission is expected to make the final decision in the coming months. The six-week schedule is already approved in the EU for certain patients receiving Libtayo after surgery and radiation to reduce the risk of high-risk cutaneous squamous cell skin cancer returning.Read Announcement